October 6, 2009 (FinancialWire) — Dr. Eric von Hofe, PhD, president of Antigen Express, Inc., the wholly-owned immunotherapeutics subsidiary of Generex Biotechnology Corp. (NASDAQ: GNBT) (www.generex.com), is currently featured on the Homeland Security Television Channel, an on-demand television network dedicated to homeland security and global development.

The segment can be viewed online at www.hstvchannel.com and will be available at www.generex.com.

Interviewed by program host and executive producer Dan Verton in an episode titled “2009 Influenza Pandemic Preparedness,” Dr. von Hofe discussed the shifting types of flu strains, resulting in new vaccines every season, and distinguished vaccines from antiviral agents and methods that would help cut down on the transmission of the H1N1 virus.

Antigen Express is developing novel immunotherapeutic and prophylactic vaccines for influenza. The company has obtained broad and strong patent coverage for its proprietary platform technologies, which would manufacture modified peptide vaccines by an entirely synthetic process, in contrast with egg-based or cell-culture-based vaccines that require expensive, extensive and labor-intensive manipulation.

“The H1N1 virus has tremendous infectivity in people and was cause for alarm,” noted von Hofe. “While H5N1 avian influenza has had a limited impact on humans, the H1N1 virus has shown itself to be highly contagious in humans and might come back.”

Dr. von Hofe described best practices for steering clear of the virus and also provided commentary on the new clinical trials approved by the FDA that look at a one-dosage vaccination that would benefit the most vulnerable age demographics, including pregnant women and children six months of age through 24 years of age.

Antigen Express’s entirely synthetic vaccine platform reduces cost and increases both the speed and quantity of production. This is of particular benefit in meeting rapidly emerging viral threats such as the potentially pandemic H5N1 avian and H1N1 swine influenzas. Vaccines developed using this platform are already in various stage clinical trials for avian flu, as well as prostate, breast and ovarian cancers.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.